537 filings
Page 2 of 27
6-K
6xaus3ur84dsy9t
30 Aug 23
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate
7:15am
6-K
rddp60kl
30 Aug 23
Current report (foreign)
6:45am
6-K
jogt 6mqky1t1jsvts
8 Aug 23
Current report (foreign)
5:25pm
6-K
nm48hqyve7desbr0eg
17 Jul 23
BioLineRx Announces Initiation of Randomized Phase 2 Clinical Trial in First Line Metastatic
7:10am
6-K
3s0ft4e8t0xnoh7ygjym
23 Jun 23
Notice of Annual General Meeting of Shareholders
4:16pm
6-K
gmwi0g
24 May 23
BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate
7:06am
6-K
70fqflvocx85 jfy7y3d
25 Apr 23
Current report (foreign)
7:07am
6-K
xgpbq5pct
17 Apr 23
BioLineRx Announces Publication in Nature Medicine of its GENESIS Phase 3 Clinical Trial Data Evaluating
11:08am
6-K
xzwk 0kcmphp
22 Mar 23
BioLineRx Reports 2022 Financial Results and Recent Corporate
7:31am
6-K
3ty2 373uh5d0fqus6ed
6 Mar 23
BioLineRx Announces Clinical Trial Collaboration with Washington University School of
7:09am
S-8
eq38ga8q
20 Jan 23
Registration of securities for employees
4:31pm
6-K
6lpbu41s9pk6
4 Jan 23
BioLineRx Appoints Tami Rachmilewitz, M.D., as Chief Medical Officer
7:06am
6-K
xnv649fdq
20 Dec 22
BioLineRx Announces Results from Phase 1/2a Study of Investigational
7:08am
6-K
0o5u x28h9
15 Nov 22
BioLineRx Reports Third Quarter 2022 Financial Results and Recent Corporate
7:07am
6-K
evzzcxnoqvcfsiweryq
10 Nov 22
Current report (foreign)
7:08am
6-K
n3ejdwcbd2jxvye7y pg
4 Nov 22
BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification
4:35pm
6-K
8lqgq3v5o8ew
3 Nov 22
BioLineRx Announces Presentations on Cost-Effectiveness of Motixafortide in Multiple Myeloma
9:20am
6-K
wk7g51m
27 Sep 22
BioLineRx Announces U.S. Commercialization Plan for APHEXDA (Motixafortide) in Stem Cell Mobilization
7:00am
6-K
vpy0av2w6c9np32jr nm
21 Sep 22
Current report (foreign)
8:00am